Findings

What do systematic reviews say?

7 questions · 7 findings · 3 reviews · Hypertension

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 1 · 14.3%Low 1 · 14.3%Moderate 2 · 28.6%High 3 · 42.9%

0.05 mg/d · participants with normal or abnormal lipid profiles

1 finding from 1 review

Cerivastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 569 participants
High

0.05 mg/d · participants with normal or abnormal lipid profiles

1 finding from 1 review

Cerivastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 504 participants
Very low

0.05 mg/d · participants with normal or abnormal lipid profiles

1 finding from 1 review

Cerivastatin for lowering lipids 2020 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1811 participants
High

Systolic BP ‐ Aliskiren 75 mg vs. placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1100 participants
Moderate

Diastolic BP ‐ Aliskiren 75 mg vs placebo · primary hypertension

1 finding from 1 review

Blood pressure lowering efficacy of renin inhibitors for primary hypertension 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1100 participants
Moderate

LDL‐Cholesterol rosuvastatin 2.5 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 450 participants
Low

LDL‐Cholesterol rosuvastatin 5 mg/day · participantswith normal or abnormal lipid profiles

1 finding from 1 review

Rosuvastatin for lowering lipids 2014 · Cochrane Headline outcomes only
no estimate extracted
25 studies · 2602 participants
High